Details

Autor(en) / Beteiligte

• Trotta, Gentiana Elena
• Ciangola, Giulia
• Cerroni, Ilaria
• Mezzanotte, Valeria
• Nunzi, Andrea
• Anemona, Lucia
• Savino, Luca
• De Angelis, Gottardo
• Mariotti, Benedetta
• Bonanni, Fabrizio
• Meddi, Elisa
• Zizzari, Annagiulia
• Rapisarda, Vito Mario
• Mangione, Ilaria
• Bruno, Antonio
• Cantonetti, Maria
• Venditti, Adriano
• Cerretti, Raffaella

Titel

Fatal acute graft-versus-host disease in Sézary Syndrome treated with Mogamulizumab and hematopoietic cell transplantation

Ist Teil von

• Current research in translational medicine, 2024-09, Vol.72 (3), p.103452, Article 103452

Ort / Verlag

France: Elsevier Masson SAS

Erscheinungsjahr

2024

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Sézary syndrome (SS) is a rare and aggressive T-cell lymphoma with a poor prognosis in advanced stages. Allogeneic hematopoietic cell transplantation (allo-HCT) offers a potential cure, but complications such as graft-versus-host disease (GvHD) remain a clinical challenge. Mogamulizumab, a humanized anti-CC chemokine receptor 4 (CCR4) antibody, is sometimes used as a bridge to transplantation, but its potential interactions with allo-HCT are unclear. This report describes the case of a 37-year-old man with advanced SS who received mogamulizumab therapy followed by allo-HCT from an HLA-identical sibling donor. The patient developed severe gastrointestinal acute GvHD, which was treated with steroids and infliximab. However, the condition rapidly progressed to severe intestinal symptoms and life-threatening haemorrhagic shock, ultimately resulting in the patient's death. This case highlights a potential link between mogamulizumab and severe acute GvHD promoted by drug-induced suppression of regulatory T cells. Further research is required to fully understand the interaction between mogamulizumab and allo-HCT and to determine whether it is an optimal approach as a bridge to transplant therapy. This paradigmatic case suggests the need of personalizing transplant strategies by selecting appropriate conditioning therapy and GvHD prophylaxis to minimize potential toxicity.